X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock investors purchased 2,515 put options on the stock. This represents an increase of 132% compared to the typical daily volume of 1,084 put options.
X4 Pharmaceuticals Stock Down 6.4 %
XFOR traded down $0.07 on Monday, reaching $1.09. The company's stock had a trading volume of 21,866,198 shares, compared to its average volume of 2,553,008. The company has a market capitalization of $183.05 million, a price-to-earnings ratio of -1.97 and a beta of 0.49. X4 Pharmaceuticals has a fifty-two week low of $0.57 and a fifty-two week high of $2.58. The company has a quick ratio of 5.34, a current ratio of 5.34 and a debt-to-equity ratio of 1.07. The stock has a 50 day moving average of $1.14 and a two-hundred day moving average of $0.93.
X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.05. As a group, analysts forecast that X4 Pharmaceuticals will post -0.47 EPS for the current fiscal year.
Insider Activity at X4 Pharmaceuticals
In related news, CFO Adam S. Mostafa sold 27,721 shares of X4 Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now owns 52,500 shares in the company, valued at approximately $53,025. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Adam S. Mostafa sold 27,721 shares of the firm's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $1.01, for a total transaction of $27,998.21. Following the completion of the transaction, the chief financial officer now directly owns 52,500 shares in the company, valued at approximately $53,025. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 49,678 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $0.88, for a total transaction of $43,716.64. Following the sale, the chief executive officer now directly owns 765,068 shares in the company, valued at approximately $673,259.84. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 185,708 shares of company stock worth $170,428. Company insiders own 1.08% of the company's stock.
Institutional Investors Weigh In On X4 Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC grew its position in X4 Pharmaceuticals by 38.8% in the 4th quarter. SG Americas Securities LLC now owns 47,668 shares of the company's stock valued at $40,000 after buying an additional 13,328 shares during the last quarter. Barclays PLC lifted its holdings in shares of X4 Pharmaceuticals by 334.8% in the 3rd quarter. Barclays PLC now owns 382,134 shares of the company's stock valued at $417,000 after buying an additional 294,255 shares during the period. GSA Capital Partners LLP acquired a new position in X4 Pharmaceuticals during the third quarter worth $678,000. Stonepine Capital Management LLC raised its position in X4 Pharmaceuticals by 14.5% in the third quarter. Stonepine Capital Management LLC now owns 5,273,685 shares of the company's stock worth $5,748,000 after acquiring an additional 668,422 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC boosted its position in shares of X4 Pharmaceuticals by 6.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 16,915,784 shares of the company's stock worth $14,184,000 after purchasing an additional 955,196 shares in the last quarter. 72.03% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of X4 Pharmaceuticals in a research note on Friday, March 22nd.
Check Out Our Latest Report on X4 Pharmaceuticals
About X4 Pharmaceuticals
(
Get Free Report)
X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.
Featured Stories
Before you consider X4 Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and X4 Pharmaceuticals wasn't on the list.
While X4 Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
